Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
- PMID: 25865655
- PMCID: PMC4720061
- DOI: 10.4143/crt.2014.262
Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
Abstract
Purpose: The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications.
Materials and methods: We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed.
Results: Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2- tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2- tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2- throughout. The HR+/HER2- to TN group had significantly poorer recurrence-free survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN throughout had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: hazard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2-showed improved comparable survival outcomes.
Conclusion: Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.
Keywords: Breast neoplasms; Molecular subtype; Neoadjuvant chemotherapy; Receptor status.
Conflict of interest statement
Conflict of interest relevant to this article was not reported.
Figures
Similar articles
-
Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.Cancer Res Treat. 2016 Oct;48(4):1363-1372. doi: 10.4143/crt.2015.456. Epub 2016 Feb 18. Cancer Res Treat. 2016. PMID: 26910473 Free PMC article.
-
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.Ann Surg Oncol. 2015 Dec;22 Suppl 3(Suppl 3):S495-501. doi: 10.1245/s10434-015-4697-7. Epub 2015 Jul 1. Ann Surg Oncol. 2015. PMID: 26130454 Free PMC article.
-
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.Breast Cancer Res. 2016 Aug 5;18(1):82. doi: 10.1186/s13058-016-0742-0. Breast Cancer Res. 2016. PMID: 27495815 Free PMC article.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors.Cancers (Basel). 2020 Jul 22;12(8):2012. doi: 10.3390/cancers12082012. Cancers (Basel). 2020. PMID: 32708049 Free PMC article. Review.
Cited by
-
Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.Diagn Pathol. 2024 Mar 20;19(1):53. doi: 10.1186/s13000-024-01451-y. Diagn Pathol. 2024. PMID: 38509525 Free PMC article.
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy.Breast Care (Basel). 2022 Oct;17(5):501-507. doi: 10.1159/000524698. Epub 2022 Apr 27. Breast Care (Basel). 2022. PMID: 36684405 Free PMC article.
-
Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy.Taehan Yongsang Uihakhoe Chi. 2020 Mar;81(2):428-435. doi: 10.3348/jksr.2020.81.2.428. Epub 2020 Mar 31. Taehan Yongsang Uihakhoe Chi. 2020. PMID: 36237394 Free PMC article.
-
A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers.Ecancermedicalscience. 2022 May 4;16:1382. doi: 10.3332/ecancer.2022.1382. eCollection 2022. Ecancermedicalscience. 2022. PMID: 35919235 Free PMC article.
References
-
- Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102. - PubMed
-
- Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol. 2004;22:2303–12. - PubMed
-
- Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011;29:594–8. - PubMed
-
- van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37:422–30. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous